Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil

Carolina Gomes Freitas, Michael Walsh, Álvaro Nagib Atallah, Carolina Gomes Freitas, Michael Walsh, Álvaro Nagib Atallah

Abstract

Background: Warfarin is a commonly used anticoagulant. Whether a given dose of the different formulations of Brazilian warfarin will result in the same effect on the international normalized ratio (INR) is uncertain. The aim of the WARFA trial is to determine whether the branded and two generic warfarins available in Brazil differ in their effect on the INR.

Methods: WARFA is a cross-over RCT comparing three warfarins. The formulations tested are the branded Marevan® (Uniao Quimica/Farmoquimica) and two generic warfarin (manufactured respectively by Uniao Quimica Farmaceutica Nacional and Laboratorio Teuto Brasileiro). All of them were manufactured in Brazil, are available in all settings of the Brazilian healthcare system and were purchased from retail drugstores. Eligible participants had atrial fibrillation or flutter, had been using warfarin for at least 2 months with a therapeutic range of 2.0-3.0 and had low variability in INR results during the 1st period of the trial. Our primary outcome, for which we have an equality hypothesis, is the difference between warfarins in the mean absolute difference between two INR results, obtained after three and 4 weeks with each drug. Our secondary outcomes, that will be tested for inequality (except for the mean INR, which will be tested for equality), include the difference in the warfarin dose, and time in therapeutic range. Clinical events and adherence were also recorded and will be reported.

Discussion: To our knowledge, WARFA will be the first comparison of the more readily applicable INR results between branded and generic warfarins in Brazil. WARFA is important because warfarins are commonly switched between in the course of a chronic treatment in Brazil. Final results of WARFA are expected in May 2017.

Trial registration: ClinicalTrials.gov NCT02017197 . Registered 11 December 2013.

Keywords: Atrial fibrillation; Brazil; Crossover; Generic drug; Generic drugs; Randomized controlled trial crossover design; Randomized crossover trial; Statistical analysis plan; Therapeutic equivalence; Warfarin.

References

    1. Storpirtis S. Princípios de biodisponibilidade, bioequivalência, equivalência farmacêutica e terapêutica de medicamentos. In: Guilhoto LM, Storpirtis S, editors. Atualização terapêutica: o impacto da diversificação de formulações de drogas antiepiléticas na prática clínica. São Paulo: Leitura Médica; 2010. pp. 15–44.
    1. World Health Organization. Multisource (generic) pharmaceutical products . Guidelines on registration requirements to establish interchangeability. Geneva: World Health Organization; 2015.
    1. Canada H. Bureau of Policy, science and international programs, therapeutic products directorate. GUIDANCE DOCUMENT comparative bioavailability standards: formulations used for systemic effects. 2012.
    1. Agência Nacional de Vigilância Sanitária (BR) RDC n° 37, de 3 de agosto de 2011. Diário Oficial da União. 2011;150(Seção 1):117–119.
    1. Agência Nacional de Vigilância Sanitária (BR) Resolução-RE 1170, de 19 de abril de 2006. Diário Oficial da União. 2006;77(Seção 77):101–102.
    1. Siqueira AL, Wada CY, Chiann C, Bernasconi G, Ferreira KA, editors. Etapa Estatística. In: Agência Nacional de Vigilância Sanitária (BR), Gerência Geral de Inspeção e Controle de Medicamentos e Produtos. Manual de boas práticas em biodisponibilidade: bioequivalência. 1st ed. Brasília: ANVISA; 2002. Módulo 3.
    1. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011;31(4):386–393. doi: 10.1592/phco.31.4.386.
    1. Henderson JD, Esham RH. Generic substitution: issues for problematic drugs. South Med J. 2001;94(1):16–21. doi: 10.1097/00007611-200194010-00003.
    1. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. Clin Ther. 2005;27(3):309–319. doi: 10.1016/j.clinthera.2005.03.004.
    1. Namazi MH, Yousefi ZK, Shirazi MG, Shaykholeslami M, Vakili H, Moatamedi MR, et al. Comparison of the clinical efficacy of three brands of warfarin. Indian J Pharm. 2004;36(6):360–362.
    1. Neutel JM, Smith DH. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovascular reviews and reports. 1998;19(2):49–59.
    1. Weibert RT, Yeager BF, Wittkowsky AK, Bussey HI, Wilson DB, Godwin JE, et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann Pharmacother. 2000;34(9):981–988. doi: 10.1345/aph.10068.
    1. Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother. 2005;39(7–8):1188–1193. doi: 10.1345/aph.1G003.
    1. Niazi SK. Bioequivalence regulatory compliance. Handbook of pharmaceutical manufacturing formulations: uncompressed solid products. 2. Boca Raton: CRC Press; 2016. pp. 104–126.
    1. Jiang W, Yu LX. Bioequivalence for narrow therapeutic drugs. In: Yu LX, Li B, editors. FDA Bioequivalence standards. New York: Springer; 2014. pp. 191–216.
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584.
    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104. doi: 10.1161/CIR.0000000000000040.
    1. Micromedex 2.0. Truven Health Analytics; Greenwood Village. 2017. . Acessed 23 Mar 2017.
    1. Agência Nacional de Vigilância Sanitária (BR). Medicamentos Genéricos Registrados. In: Listas de medicamentos genéricos registrados. Agência Nacional de Vigilância Sanitária. 2015. . Acessed 26 Oct 2015.
    1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in patients with Atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/NEJMoa1310907.
    1. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e326S–e350S. doi: 10.1378/chest.11-2298.
    1. Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res. 2012;129(6):715–719. doi: 10.1016/j.thromres.2011.08.024.
    1. World Health Organization . WHO expert committee on biological standardization: twenty-eighth report. Geneva: World Health Organization; 1977.
    1. Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20(2):187–191. doi: 10.1016/j.jcrc.2005.04.005.
    1. Majerus PW, Tollefsen DM. Anticoagulantes, trombolíticos e fármacos antiplaquetários. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman, As bases farmacológicas da terapêutica. 10. Rio de Janeiro: McGraw-Hill; 2005. pp. 1141–1158.
    1. Chiann C. Biofarmacotécnica. Rio de Janeiro: Guanabara Koogan; 2011. Planejamento e análise estatistica dos estudos de biodisponibilidade e bioequivalência de medicamentos; pp. 124–134.
    1. Jones B, Kenward MG. Analysis of continuous data. In: Design and analysis of cross-over trials. 2nd ed. London: Chapman and Hall; 2003. p. 205-280.
    1. Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley & Sons; 1995. The size of a clinical trial; pp. 123–138.
    1. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276–281.
    1. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x.
    1. Brown H, Prescott R. Applied mixed models in Medicine. 2. Chichester: John Wiley & Sons; 2006.
    1. Sackett DL. The principles behind the tactics of performing therapeutic trials. In: Haynes RB, Sackett DL, Guyatt GH, Tugwell P, editors. Clinical epidemiology: how to do clinical practice research. 3rd. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 173–243.
    1. Freeman PR. The performance of the two-stage analysis of two-treatment, two-period crossover trials. Stat Med. 1989;8(12):1421–1432. doi: 10.1002/sim.4780081202.
    1. Piatandosi S. Clinical trials: a Methodologic perspective. Hoboken: John Wiley & Sons; 1997. Crossover designs; pp. 515–528.
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(23):2440–2492. doi: 10.1161/CIR.0000000000000029.
    1. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325(7365):652–654. doi: 10.1136/bmj.325.7365.652.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel